-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
TRK Inhibition in TRK Fusion–Positive Lung Cancers
By Alexander Drilon, MD Posted: February 12, 2020 The receptor tyrosine kinases TRKA/B/C are encoded by the genes NTRK1/2/3. TRK fusions are oncogenic drivers of various adult and pediatric cancers. These fusions are found at high frequencies (> 90% in select series) in rare cancers such as secretory carcinoma and at lower frequencies in more…